Daiichi Sankyo Company, Limited, was established on September 28, 2005 as the joint holding company of two major Japanese pharmaceutical companies - Sankyo Company, Limited and Daiichi Pharmaceutical Co., Ltd. Daiichi Sankyo is a global pharmaceutical innovator, continuously generating innovative drugs and services and maximizing its corporate value. Sankyo and Daiichi Pharmaceutical have a broad range of major drug products on the Japanese market, including the antihypertensive Benicar (olmesartan medoxomil) and the synthetic antibacterial agent Cravit (levofloxacin). Both companies have used their cumulative knowledge and expertise in the field of cardiovascular disease as a foundation for developing an abundant product lineup and R&D pipeline. 

Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)

Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)